This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish: PATENT SYSTEM APPLIED TO DRUGS General field: Law/Patents Detailed field: Medical: Pharmaceuticals
Source text - English EL SISTEMA DE PATENTES APLICADO A LOS MEDICAMENTOS
Un tercio de la población mundial no tiene acceso regular a medicamentos esenciales y esta proporción puede llegar a más de la mitad de la población en algunos países en desarrollo. La Organización Mundial de la Salud (OMS), Unicef y el Programa Conjunto de las Naciones Unidas sobre el VIH/sida (ONUSIDA), en su informe de 2012 (1), estimaron que de los 34 millones de personas que viven con el virus de inmunodeficiencia humana (VIH) y que deberían estar recibiendo tratamiento, solo 8 millones tenían acceso a la terapia a finales de 2012 (2).
Esta situación, como lo afirma Eric Goemaere, en el libro de Boulet, Garrison y Hoen (3), se debe en gran parte a los altos costos de los medicamentos protegidos por patentes:
Cómo me indigna oír que los derechos de las patentes no constituyen una barrera al tratamiento aquí en Sudáfrica. He visto hombres y mujeres jóvenes morir víctimas de tumores cerebrales asociados al SIDA, tras padecer insoportables dolores de cabeza. He visto niños llenos de cicatrices provocadas por dermatitis asociadas al SIDA, incapaces de dormir por el dolor. Sabía que una terapia antirretroviral podía ayudarles, y que la única barrera que lo impedía era el coste del medicamento patentado. (3)
Las patentes para productos farmacéuticos han sido uno de los temas sobre el acceso a medicamentos esenciales más debatidos desde la creación de la Organización Mundial del Comercio (OMC) en 1995 y la firma del Acuerdo sobre los Aspectos de los Derechos de Propiedad Intelectual relacionados con el Comercio (ADPIC).
Las patentes no son la única barrera al acceso a medicamentos pero cada vez más pueden ser un factor determinante, en la medida que las patentes otorgan un monopolio sobre el medicamento al titular de la patente, que posee de libertad para fijar los precios. Esta libertad para fijar los precios de los productos patentados ha llevado a que un gran número de medicamentos no se encuentre disponible a la gran mayoría de la población mundial que vive en los países en desarrollo.
Translation - Spanish PATENT SYSTEM APPLIED TO DRUGS
One third of the world's population has no regular access to essential drugs, this may account for more than half the population in some developing countries. The World Health Organization (WHO), Unicef and the Joint Program of the United Nations on HIV/aids (UNAIDS) have estimated, in a report in 2012 (1), that out of the 34 million people who live with the human immunodeficiency virus (HIV), who should be receiving treatment, only 8 million had access to the therapy towards the end of 2012 (2).
As stated by Eric Goemaere in the Boulet, Garrison and Hoen's book (3), this situation is mostly due to the high prices of patent-protected drugs:
It makes me so angry to hear the patent rights don't create a barrier to treatment here in South Africa. I have seen young men and women die as victims of AIDS-related brain tumors after suffering unbearable headaches. I have seen kids full of scars caused by dermatitis related to AIDS, unable to sleep because of the pain. I knew that an antiretroviral therapy could help them, and that the only obstacle was the cost of a patent-protected drug. (3)
Patents for pharmaceutical products have been one of the most debated topics about access to essential drugs since the creation of the World Trade Organization (WTO) in 1995 and the signing of the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement.
Patents are not the only obstacle to drug access, but they may increasingly become a more determining factor as patents provide monopoly over the drug to the patent holder, who has the freedom to set prices. This freedom to set product price has caused a large number of drugs to be unavailable for the majority of the world population living in developing countries.
More
Less
Translation education
Bachelor's degree - Lanús National University (ARG)
Experience
Years of experience: 11. Registered at ProZ.com: May 2013.
My name is Martín Rost, and I am a professional English-Spanish linguist originally from Buenos Aires, Argentina (native Spanish speaker)! I hold a Bachelor's degree in Sworn Translation and have worked as a freelancer since 2013. Now I am based in Dublin, Ireland.
Over the last decade, I have collaborated on many projects as a translator, editor, and proofreader. But that is not all! I have also worked on MTPE, transcription, and subtitling projects. This full range of services, combined with my expertise in legal and technical translation, have made me a well-rounded professional who is actively involved in this wonderful industry.
You can always expect a genuine professional attitude from me. My attention to detail and commitment to providing excellence to clients are core values in the foundation of my work ethic.
Do not hesitate to contact me! I look forward to collaborating with you!
Keywords: Spanish, English, LA, Español, Castellano, Inglés, legal, medical, IT
Expertise